Skip to main content Help with accessibility Skip to main navigation

PSORIATIC ARTHRITIS: sequential use of high cost agents

Last Updated: 28 November 2018

Body System: Musculoskeletal system

Red

The Pan Mersey Area Prescribing Committee recommends the sequential use of high cost agents, adalimumab, apremilast▼, certolizumab, etanercept, golimumab, infliximab, ixekizumab▼, secukinumab▼, tofacitinib▼ and ustekinumab in the management of psoriatic arthritis (PsA) in accordance with the recommendations below, and the accompanying flowchart.

PSORIATIC ARTHRITIS and PERIPHERAL SPONDYLOARTHROPATHY: high cost drugs pathway